Resident of the SEZ Technopolis Moscow will invest more than 40 million rubles in the development of the production of medicines

The Rada-Pharma company at the end of 2020 received the status of a resident of the special economic zone and plans to invest more than 40 million rubles in the launch of a new production line by 2022. The company specializes in the production of drugs and medical devices based on chlorophyll for photodynamic therapy, which is used in the treatment of oncological, gynecological and dermatological diseases as informed by Alexander Prokhorov, Head of the Department for Investment and Industrial policy of Moscow. The method of photodynamic therapy is based on the selective accumulation of the active drug substance in malignant neoplasms, which are destroyed when interacting with laser radiation of a certain wavelength, without damaging healthy cells. “Now Rada-Pharma produces about 12.5 thousand drugs and medical devices annually, and by the end of 2026, the commissioning of a new line will increase production by a third, to 17 thousand pieces. Currently, the share of Rada-Pharma in the domestic market of drugs for photodynamic therapy is about 66 percent”, said the Head of the Department. The status of a resident of the special economic zone Technopolis Moscow will give the company the opportunity to significantly save on taxes and other obligatory payments every year: the company will have access to a reduced income tax, duty-free imports and a zero rate on property and transport. The company plans to use the funds saved in the budget to improve material and technical support, create new developments and training programs. Thanks to investments, the resident also plans to increase its share in the domestic market said Gennady Degtev, CEO of SEZ Technopolis Moscow. “Rada-Pharma has been localized on the territory of the special economic zone since 2014. The company's products are supplied to public hospitals, private clinics and pharmacies in more than 50 regions of the country. Obtaining resident status and all tax preferences, introducing a new line of equipment and keeping prices by a quarter lower than those of competitors will allow the company to increase its share in the Russian market of drugs for photodynamic therapy up to 70 percent”, specified Gennady Degtev.  ---------------------- Press service of the SEZ "Technopolis Moscow" Phone: +7 916 516-15-46 Mail: pr@technomoscow.ru [ mailto:pr@technomoscow.ru ] Subscribe to the SEZ "Technopolis Moscow" in social networks, follow the main news of the SEZ in telegram-channel [ https://t.me/technopolismoscow ]  and receive all the most important news delivered to your mail in our weekly newsletter [ http://events.technomoscow.ru/subscribe/?utm_source=site_technomoscow ] .